Entest Group Inc

[zigzagman]

ENTB has completed pre-clinical research indicating that, by inhibiting NR2F6, cancer stem cells can be converted into normal cells, thus potentially curing the patient of cancer. Additionally, activators of NR2F6 have the potential to provide relief from autoimmune diseases such as arthritis. They have licensed this associated technology out to Zander Therapeutics, primarily for use by that company’s wholly owned subsidiary, Entest BioMedical Inc. (ENTB), a publicly traded biotechnology company focused on veterinary medicine.

According to a recent release, “NR2F6 is a molecular switch known as an ‘orphan nuclear receptor’, which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Zander Therapeutics, Inc. has been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize veterinary applications of NR2F6.